Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 15 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.10 Insider Own2.65% Shs Outstand61.00M Perf Week-6.47%
Market Cap1.23B Forward P/E- EPS next Y-2.94 Insider Trans-8.28% Shs Float59.50M Perf Month-8.72%
Income-126.09M PEG- EPS next Q-0.83 Inst Own102.54% Short Float9.98% Perf Quarter-0.94%
Sales168.34M P/S7.30 EPS this Y-66.34% Inst Trans-2.45% Short Ratio8.32 Perf Half Y8.76%
Book/sh10.96 P/B1.83 EPS next Y15.08% ROA-14.02% Short Interest5.94M Perf Year-30.77%
Cash/sh9.71 P/C2.07 EPS next 5Y- ROE-18.06% 52W Range16.49 - 30.21 Perf YTD-5.28%
Dividend Est.- P/FCF18.44 EPS past 5Y-9.81% ROI-16.98% 52W High-33.43% Beta0.77
Dividend TTM- Quick Ratio7.36 Sales past 5Y70.11% Gross Margin93.17% 52W Low21.95% ATR (14)0.96
Dividend Ex-Date- Current Ratio7.36 EPS Y/Y TTM-127.34% Oper. Margin-81.54% RSI (14)36.49 Volatility3.78% 4.21%
Employees280 Debt/Eq0.12 Sales Y/Y TTM2.28% Profit Margin-74.90% Recom1.46 Target Price35.83
Option/ShortYes / Yes LT Debt/Eq0.11 EPS Q/Q-56.17% Payout- Rel Volume0.54 Prev Close20.48
Sales Surprise-42.44% EPS Surprise-192.45% Sales Q/Q106.80% EarningsFeb 27 AMC Avg Volume713.55K Price20.11
SMA20-7.79% SMA50-8.77% SMA200-5.07% Trades Volume386,573 Change-1.81%
Date Action Analyst Rating Change Price Target Change
Feb-28-24Downgrade Piper Sandler Overweight → Neutral $37 → $24
May-19-23Initiated BofA Securities Buy $42
Dec-06-22Initiated Cowen Outperform
Oct-13-22Upgrade Raymond James Outperform → Strong Buy $58
Sep-21-22Initiated JP Morgan Overweight $37
Jul-06-22Resumed Canaccord Genuity Buy $50
Feb-11-22Initiated BMO Capital Markets Outperform $54
Jan-21-22Initiated SMBC Nikko Outperform $60
Dec-15-21Initiated H.C. Wainwright Buy $61
Oct-15-21Resumed BTIG Research Buy $56
Apr-09-24 08:01AM
Mar-08-24 05:01PM
Mar-07-24 05:00PM
Feb-28-24 04:01PM
08:38AM Loading…
Feb-27-24 05:20PM
Feb-20-24 04:31PM
Feb-19-24 03:37AM
Feb-15-24 10:00AM
Jan-03-24 04:01PM
08:01AM Loading…
Jan-02-24 08:01AM
Dec-30-23 05:02PM
Nov-21-23 04:01PM
Nov-09-23 02:19PM
Nov-08-23 05:21AM
Nov-07-23 04:39PM
Nov-03-23 12:01PM
Oct-31-23 04:01PM
Oct-26-23 08:01AM
Oct-17-23 04:21AM
Sep-27-23 09:01AM
Sep-19-23 04:01PM
06:01AM Loading…
Aug-08-23 06:01AM
Aug-07-23 04:02PM
Aug-03-23 05:15PM
Jul-27-23 08:01AM
Jul-03-23 08:38PM
Jun-21-23 08:00PM
Jun-18-23 10:00AM
May-30-23 06:01PM
May-09-23 01:49PM
May-08-23 05:15PM
May-01-23 04:01PM
Apr-26-23 08:00PM
Apr-17-23 01:31PM
Apr-09-23 01:19PM
Mar-14-23 04:31PM
Feb-28-23 05:10AM
Feb-25-23 07:17AM
Feb-23-23 05:25PM
Feb-20-23 10:00AM
Feb-16-23 04:01PM
Feb-07-23 04:01PM
Jan-26-23 02:33PM
Jan-09-23 08:01AM
Jan-05-23 06:30AM
Jan-04-23 04:01PM
Dec-12-22 03:44PM
Nov-30-22 09:55AM
Nov-25-22 12:00PM
Nov-10-22 04:01PM
Nov-07-22 05:25PM
Nov-03-22 09:01AM
Oct-31-22 04:01PM
Oct-28-22 11:58AM
Oct-14-22 09:41AM
Oct-06-22 08:37PM
Oct-05-22 08:01AM
Sep-09-22 08:01AM
Aug-29-22 06:35AM
Aug-03-22 05:25PM
Aug-02-22 06:30AM
Aug-01-22 11:31AM
Jul-27-22 04:01PM
Jul-01-22 11:59AM
May-26-22 05:01PM
May-13-22 09:18AM
May-07-22 09:30AM
May-06-22 10:24AM
May-05-22 05:25PM
May-04-22 10:52AM
May-03-22 07:55AM
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dahiyat Bassil IPRESIDENT & CEOMar 11 '24Sale23.502,74164,418351,894Mar 12 04:03 PM
Desjarlais John RSR. VICE PRESIDENT & CSOMar 11 '24Sale23.501,28030,082186,433Mar 12 04:05 PM
Eckert CeliaSVP, GENERAL COUNSELMar 11 '24Sale23.5085019,97745,465Mar 12 04:06 PM
Kuch John JSR. VICE PRESIDENT & CFOMar 11 '24Sale23.5084919,953121,070Mar 12 04:08 PM
GUSTAFSON KURT ADirectorMar 06 '24Option Exercise10.7315,000160,95020,007Mar 07 04:10 PM
GUSTAFSON KURT ADirectorMar 06 '24Sale23.1814,000324,4536,007Mar 07 04:10 PM
Dahiyat Bassil IPRESIDENT & CEOMar 05 '24Sale23.4312,528293,519300,097Mar 07 04:01 PM
Desjarlais John RSR. VICE PRESIDENT & CSOMar 05 '24Sale23.436,629155,311166,989Mar 07 04:05 PM
Kuch John JSR. VICE PRESIDENT & CFOMar 05 '24Sale23.434,474104,821121,919Mar 07 04:07 PM
Eckert CeliaSVP, GENERAL COUNSELMar 05 '24Sale23.433,89291,18633,226Mar 07 04:03 PM
Desjarlais John RSR. VICE PRESIDENT & CSOFeb 14 '24Option Exercise11.0511,943131,970173,618Feb 16 04:06 PM
Desjarlais John RSR. VICE PRESIDENT & CSOFeb 13 '24Option Exercise11.0568,057752,030215,783Feb 14 02:23 PM
GORMAN KEVIN CHARLESDirectorFeb 13 '24Buy19.12531,0135,060Feb 15 04:02 PM
Desjarlais John RSR. VICE PRESIDENT & CSOFeb 13 '24Sale19.3854,1081,048,743161,675Feb 14 02:23 PM
Dahiyat Bassil IPRESIDENT & CEODec 29 '23Option Exercise11.0565,001718,261357,929Dec 29 04:24 PM
Dahiyat Bassil IPRESIDENT & CEODec 29 '23Sale20.9345,000941,670312,929Dec 29 04:24 PM
Dahiyat Bassil IPRESIDENT & CEOJun 21 '23Option Exercise4.2576,012323,051325,713Jun 22 08:33 AM
Dahiyat Bassil IPRESIDENT & CEOJun 21 '23Sale26.1933,497877,286292,216Jun 22 08:33 AM